Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort

被引:10
作者
Thomas, Quentin Dominique [1 ,20 ]
Boussere, Amal [2 ]
Classe, Jean-Marc [3 ]
Pomel, Christophe [4 ]
Costaz, Helene [5 ]
Rodrigues, Manuel [6 ]
Ray-Coquard, Isabelle [7 ]
Gladieff, Laurence [8 ]
Rouzier, Roman [9 ]
Rouge, Thibault De La Motte [10 ]
Gouy, Sebastien [11 ]
Barranger, Emmanuel [12 ]
Sabatier, Renaud [13 ]
Floquet, Anne [14 ]
Marchal, Frederic [15 ]
Guillemet, Cecile [16 ]
Polivka, Valentine [2 ]
Martin, Anne-Laure [17 ]
Colombo, Pierre-Emmanuel [18 ]
Fiteni, Frederic [19 ]
机构
[1] Montpellier Univ, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[2] Montpellier Univ, Inst Canc Montpellier, Dept Biometry, Montpellier, France
[3] Inst Cancerol Ouest Ctr Rene Gauducheau, Dept Surg Oncol, St Herblain, France
[4] Univ Clermont Auvergne, Ctr Lutte Canc Jean Perrin, Dept Surg Oncol, Imagerie Mol & Strategies Theranost,UMR,INSERM,UCA, Clermont Ferrand, France
[5] Ctr Georges Francois Leclerc, Dept Surg Oncol, Dijon, France
[6] Inst Curie, Dept Med Oncol, Paris, France
[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[8] Inst Claudius Regaud IUCT O, Dept Med Oncol, Toulouse, France
[9] Ctr Francois Baclesse, Dept Surg Oncol, Caen, France
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Gustave Roussy, Dept Surg, Villejuif, France
[12] Ctr Antoine Lacassagne, Dept Surg, Nice, France
[13] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France
[14] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[15] Inst Cancerol Lorraine, Dept Surg, Nancy, France
[16] Ctr Henri Becquerel, Dept Med Oncol, Rouen, France
[17] Unicanc, Hlth Data & Partnership Dept, Paris, France
[18] Montpellier Univ, Inst Canc Montpellier, Dept Surg, Montpellier, France
[19] Univ Montpellier, Univ Hosp Nimes, IDESP Inst Desbrest Epidemiol & St Publ, Dept Med Oncol,UMR,UA11,INSERM, Montpellier, France
[20] 208 Ave Apothicaires, F-34000 Montpellier, France
关键词
Neoadjuvant; Cytoreduction; Survival; Prognosis; Propensity score; NEOADJUVANT CHEMOTHERAPY CYCLES; SURGICAL CYTOREDUCTION; OPEN-LABEL; SURVIVAL; NUMBER; MULTICENTER; BEVACIZUMAB; IMPACT; TRIAL;
D O I
10.1016/j.ygyno.2022.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemo-therapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after >= 5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. Methods. We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were com-pared using Cox model with adjustments for confounding factors provided by two propensity score methods: in-verse probability of treatment weighting (IPTW) and matched-pair analysis. Results. 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). Conclusions. Carrying IDS after >= 5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:11 / 21
页数:11
相关论文
共 38 条
[21]   Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study [J].
Liu, Ying L. ;
Zhou, Qin C. ;
Iasonos, Alexia ;
Chi, Dennis S. ;
Zivanovic, Oliver ;
Sonoda, Yukio ;
Gardner, Ginger ;
Broach, Vance ;
O'Cearbhaill, Roisin ;
Konner, Jason A. ;
Grisham, Rachel ;
Aghajanian, Carol A. ;
Abu-Rustum, Nadeem R. ;
Tew, William ;
Long Roche, Kara .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) :1915-1921
[22]   Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness [J].
Miranda, Vanessa da Costa ;
de Souza Fede, Angelo Bezerra ;
dos Anjos, Carlos Henrique ;
da Silva, Juliana Ribeiro ;
Sanchez, Fernando Barbosa ;
da Silva Bessa, Lyvia Rodrigues ;
Carvalho, Jesus de Paula ;
Abdo Filho, Elias ;
de Freitas, Daniela ;
Estevez Diz, Maria del Pilar .
GYNECOLOGIC ONCOLOGY, 2014, 132 (02) :287-291
[23]   An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication [J].
Morin, Olivier ;
Vallieres, Martin ;
Braunstein, Steve ;
Ginart, Jorge Barrios ;
Upadhaya, Taman ;
Woodruff, Henry C. ;
Zwanenburg, Alex ;
Chatterjee, Avishek ;
Villanueva-Meyer, Javier E. ;
Valdes, Gilmer ;
Chen, William ;
Hong, Julian C. ;
Yom, Sue S. ;
Solberg, Timothy D. ;
Lock, Steffen ;
Seuntjens, Jan ;
Park, Catherine ;
Lambin, Philippe .
NATURE CANCER, 2021, 2 (07) :709-+
[24]   Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602 [J].
Onda, Takashi ;
Matsumoto, Koji ;
Shibata, Taro ;
Sato, Akihiro ;
Fukuda, Haruhiko ;
Konishi, Ikuo ;
Kamura, Toshiharu ;
Yoshikawa, Hiroyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) :74-77
[25]   The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) [J].
Perol, David ;
Robain, Mathieu ;
Arveux, Patrick ;
Mathoulin-Pelissier, Simone ;
Chamorey, Emmanuel ;
Asselain, Bernard ;
Berchery, Delphine ;
Gourgou, Sophie ;
Breton, Mathias ;
Delaine-Clisant, Stephanie ;
Mons, Muriel ;
Dieras, Veronique ;
Carton, Matthieu ;
Guizard, Anne-Valerie ;
Laborde, Lilian ;
Laurent, Carine ;
Loeb, Agnes ;
Mouret-Reynier, Marie-Ange ;
Parent, Damien ;
Perrocheau, Genevieve ;
Campion, Loic ;
Velten, Michel ;
Cailliot, Christian ;
Ezzalfani, Monia ;
Simon, Gaetane .
BMJ OPEN, 2019, 9 (02)
[26]   A Phase 3 Trial of Bevacizumab in Ovarian Cancer [J].
Perren, Timothy J. ;
Swart, Ann Marie ;
Pfisterer, Jacobus ;
Ledermann, Jonathan A. ;
Pujade-Lauraine, Eric ;
Kristensen, Gunnar ;
Carey, Mark S. ;
Beale, Philip ;
Cervantes, Andres ;
Kurzeder, Christian ;
du Bois, Andreas ;
Sehouli, Jalid ;
Kimmig, Rainer ;
Staehle, Anne ;
Collinson, Fiona ;
Essapen, Sharadah ;
Gourley, Charlie ;
Lortholary, Alain ;
Selle, Frederic ;
Mirza, Mansoor R. ;
Leminen, Arto ;
Plante, Marie ;
Stark, Dan ;
Qian, Wendi ;
Parmar, Mahesh K. B. ;
Oza, Amit M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2484-2496
[27]   Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer [J].
Phillips, Andrew ;
Sundar, Sudha ;
Singh, Kavita ;
Nevin, James ;
Elattar, Ahmed ;
Kehoe, Sean ;
Balega, Janos .
EJSO, 2018, 44 (06) :760-765
[28]   Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer [J].
Ray-Coquard, I. ;
Pautier, P. ;
Pignata, S. ;
Perol, D. ;
Gonzalez-Martin, A. ;
Berger, R. ;
Fujiwara, K. ;
Vergote, I. ;
Colombo, N. ;
Maenpaa, J. ;
Selle, F. ;
Sehouli, J. ;
Lorusso, D. ;
Alia, E. M. Guerra ;
Reinthaller, A. ;
Nagao, S. ;
Lefeuvre-Plesse, C. ;
Canzler, U. ;
Scambia, G. ;
Lortholary, A. ;
Marme, F. ;
Combe, P. ;
de Gregorio, N. ;
Rodrigues, M. ;
Buderath, P. ;
Dubot, C. ;
Burges, A. ;
You, B. ;
Pujade-Lauraine, E. ;
Harter, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2416-2428
[29]   Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial [J].
Shi, Tingyan ;
Zhu, Jianqing ;
Feng, Yanling ;
Tu, Dongsheng ;
Zhang, Yuqin ;
Zhang, Ping ;
Jia, Huixun ;
Huang, Xiao ;
Cai, Yunlang ;
Yin, Sheng ;
Jiang, Rong ;
Tian, Wenjuan ;
Gao, Wen ;
Liu, Jihong ;
Yang, Huijuan ;
Cheng, Xi ;
Zang, Rongyu .
LANCET ONCOLOGY, 2021, 22 (04) :439-449
[30]   Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery [J].
Stoeckle, Eberhard ;
Bourdarias, Lionnel ;
Guyon, Frederic ;
Croce, Sabrina ;
Brouste, Veronique ;
Thomas, Laurence ;
Floquet, Anne .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) :629-636